Optimizing therapy for complex or refractory heart failure: A management algorithm☆,☆☆,★,★★
Section snippets
Optimizing Standard Therapy
Major advances in our understanding and therapy of heart failure have occurred during the last 2 decades. Well-designed large clinical trials have established the benefits of ACE inhibitors, the combination of nitrates and hydralazine, and digoxin. At the same time the potential hazards of agents such as antiarrhythmic drugs and nonsteroidal antiinflammatory agents have been recognized. This experience and evidence have been incorporated into practice guidelines, which provide sufficient
The Management Algorithm for Patients with Complex or Refractory Heart Failure
This discussion of the optimization of further therapy focuses on those patients who have persistent or recurrent limitation of routine daily activity by heart failure symptoms (New York Heart Association class III-IV) despite the initiation of standard therapies with ACE inhibitors, diuretics, and digoxin, according to the Heart Failure Clinical Practice guidelines reviewed previously.7, 21, 22 Many of those patients will have been hospitalized one or more times on these medications. It is
Patient education
Patient education should begin with a simple version of the cause, features, and prognosis of heart failure19, 20 (Table IV). Specific instructions should emphasize the positive aspects of what the patient can do including self-monitoring, employment, exercise, and sexual activity (Table V). Patients who have had major fluid retention should in general follow a 2 gm sodium diet, although negotiation may be required for patients with cultural reliance on a higher salt diet. The emphasis on fluid
Outlook for Chronic Heart Failure
The classic image of the patient with heart failure languishing with intractable dyspnea is becoming increasingly rare as comprehensive care evolves and becomes more widely available. Although the survival rates are comparable to those for severe cancer, the analogy subsequently weakens, because comfort is easier to maintain with heart failure. Most patients can live comfortable lives until death intervenes suddenly or at least rapidly. Most patients without complicating noncardiac illness can
References (78)
- et al.
The predictability of mitral regurgitation detected by doppler echocardiography in patients referred for cardiac transplantation
Am J Cardiol
(1987) - et al.
The influence of mitral regurgitation on the hemodynamic response to vasodilators in chronic congestive heart failure
Chest
(1991) - et al.
Afterload reduction with vasodilators and diuretics decreases mitral valve regurgitation during upright exercise in advanced heart failure
J Am Coll Cardiol
(1990) - et al.
Left ventricular dysfunction due to atrial fibrillation in patients initially believed to have idiopathic dilated cardiomyopathy
Am J Cardiol
(1992) - et al.
Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial
J Am Coll Cardiol
(1993) - et al.
Bedside cardiovascular examination in patients with severe chronic heart failure. Importance of rest or inducible jugular venous distension
J Am Coll Cardiol
(1993) - et al.
Metolazone and the treatment of severe refractory congestive heart failure
Lancet
(1990) - et al.
Impact of a comprehensive heart failure management program on hospital readmission and functional status of patients with advanced heart failure
J Am Coll Cardiol
(1997) - et al.
Persistent hemodynamic improvement with short-term nitrate therapy in patients with chronic congestive heart failure already treated with captopril
Am J Cardiol
(1992) - et al.
Effect of direct vasodilation with hydralazine versus angiotensin-converting enzyme inhibition with captopril on mortality in advanced heart failure: the Hy-C trial
J Am Coll Cardiol
(1992)
Improvement in exercise capacity of candidates awaiting heart transplantation
J Am Coll Cardiol
Intermittent inotropic therapy in an outpatient setting: a cost-effective therapeutic modality in patients with refractory heart failure
Am Heart J
Randomised trial of low-dose amiodarone in severe congestive heart failure
Lancet
Improving survival for patients with advanced heart failure: a study of 737 consecutive patients
J Am Coll Cardiol
The heart failure epidemic
Curr Opin Cardiol
Changing epidemiological features of cardiac failure
Br Heart J
Heart failure: a growing public health problem
J Intern Med
Mortality from congestive heart failure—United States 1980-90
MMWR
Heart and stroke facts: 1996 statistical supplement
Economic impact of heart failure in the United States: time for a different approach
J Heart Lung Transplant
Heart failure: evaluation and care of patients with left-ventricular systolic dysfunction
Guidelines for the evaluation and management of heart failure
J Am Coll Cardiol
Differences in practice patterns in managing heart between cardiologists, family practitioners, and internists
J Am Coll Cardiol
Management of heart failure. III. The role of revascularization in the treatment of patients with moderate or severe left ventricular systolic dysfunction
JAMA
The role of coronary revascularization in the management of heart failure: identification of candidates and review or results
Curr Opin Cardiol
Beneficial effects of vasodilator agents in severe mitral regurgitation due to dysfunction of subvalvar apparatus
Circulation
Low-dose amiodarone for atrial fibrillation
Am J Cardiol
Heart failure due to preserved systolic function: a common and costly clinical entity
Am Heart J
Management of heart failure. II. Counseling, education, and lifestyle modifications
JAMA
Heart failure
Management of heart failure. I. Pharmacologic treatment
JAMA
Chronic heart failure: diagnosis and management
Discontinuation of chronic diuretic therapy in stable congestive heart failure secondary to coronary artery disease or to idiopathic dilated cardiomyopathy
Am J Cardiol
Overview of randomized trials of angiotensin-converting enzyme inhibitors on morality and morbidity in patients with heart failure
JAMA
The effect of digoxin on mortality and morbidity in patients with heart failure
N Engl J Med
Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors
N Engl J Med
Therapy tailored for symptomatic heart failure
Heart Failure
Freedom from congestion at one month predicts good two-year survival after hospitalization for class IV heart failure
Circulation
The limited reliability of physical signs for the estimation of hemodynamics in chronic heart failure
JAMA
Cited by (93)
Management of oral chronic pharmacotherapy in patients hospitalized for acute decompensated heart failure
2014, International Journal of Cardiology2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation
2009, Journal of the American College of Cardiology2009 Focused Update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation
2009, Journal of the American College of CardiologyInotropes in the management of acute heart failure
2008, Critical Care MedicineDrug Treatment of Heart Failure in Children: Gaps and Opportunities
2022, Pediatric DrugsUpdate of the guidelines for cardiopulmonary resuscitation and emergency cardiovascular care of the Brazilian Society of Cardiology - 2019
2019, Arquivos Brasileiros de Cardiologia
- ☆
From the aCardiomyopathy and Heart Failure Program, Cardiovascular Divison, Department of Medicine, Brigham and Women's Hospital; the bDepartment of Medicine and Cardiovascular Research Institute of the University of California, San Francisco and the Cardiology Section of the San Francisco Department of Veterans Affairs Medical Center; and cthe Cardiovascular Division, University of Minnesota Hospital.
- ☆☆
Supported in part by the FE Rippel Foundation and the Department of Veterans Affairs Research Service.
- ★
Reprint requests: Lynne W. Stevenson, MD, Cardiovascular Division, Brigham and Women's Hospital, 75 Francis St., Boston, MA 02115.
- ★★
4/0/90086